Rivastigmine for vascular cognitive impairment (Q24247146)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Rivastigmine for vascular cognitive impairment (English)

0 references

main subject

cognitive dysfunction

1 reference

2

0 references

author name string

David Craig

series ordinal

1

0 references

publication date

19 April 2004

0 references

published in

0 references

cites work

Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Rivastigmine in subcortical vascular dementia: an open 22-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Rivastigmine in vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Cholinesterase inhibitors and vascular dementia: another string to their bow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Frontal-subcortical circuits and human behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Donepezil for vascular cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Clinical features of MRI-defined subcortical vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

The Association between White Matter Lesions on Magnetic Resonance Imaging and Noncognitive Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004744.PUB2